한글목차

미국의 MRD 검사 시장 규모는 2024년부터 2030년의 예측기간 동안 CAGR 14.18%을 나타내며, 2030년에는 16억 6,750만 달러의 규모에 이를 것으로 예측되고 있습니다.

미국의 MRD 검사 시설은 2023년 세계 MRD 검사 시설 전체의 39.53% 점유율을 보여줍니다.

MRD 검사는 특정 암, 특히 백혈병 및 림프종 추적에 중요한 역할을 합니다. 미국에서는 많은 검사 시설과 의료 기관이 MRD 검사 서비스를 제공합니다. 이러한 유형의 검사는 종양 진단 및 치료 모니터링에 필수적인 요소로 발전해 왔습니다. 잔존 암세포의 고감도 검출 등 그 혁신적인 능력은 차세대 시퀀싱(NGS), 디지털 PCR, 유동세포계측법 등 첨단기술의 채용을 뒷받침하고 있습니다.

미국 내 시설의 지리적 분포에 대한 인사이트

• 미국 내 MRD 검사 시설의 분포는 접근 및 이용의 지역 격차를 돋보이게 합니다. 캘리포니아, 뉴욕, 텍사스 등의 주들은 견고한 건강 관리 인프라와 높은 암 이환율을 바탕으로 MRD 검사 건수를 선도하고 있습니다.
• 반대로 캔자스 주와 네바다 주와 같이 인구가 적은 주에서는 검사 건수가 적고 1인당 이용률은 경쟁력을 유지하고 있습니다. CAP 및 CLIA 인증을 받은 인증 시설은 주류를 차지하며 고품질 검사 및 엄격한 규제 기준을 준수합니다.

본 보고서에서는 미국의 약 200개의 MRD 검사 시설 시장을 조사했으며,, 미국의 MRD 검사 개요, MRD 검사 시설프로파일, 시장 규모 추이와 예측, 기술 전망, 시장 영향요인 분석 등을 정리했습니다.

이 설문조사는 미국의 약 200개 검사 시설 프로파일링에 중점을 두고 전략적 계획, 시장 분석 및 벤치마킹에 귀중한 인사이트를 제공합니다. 이해관계자는 경영 지표를 비교하고, 충분한 서비스를 받지 못한 지역을 파악하고, 제휴 기회를 찾을 수 있습니다. 상세한 검사 데이터는 임상 워크플로우 최적화, 첨단 기술 채택, 업계 표준과의 일치에 도움이 됩니다. 또한 규제 요건의 준수를 지원하고 자금 조달의 홍보를 강화합니다.

조사 카테고리 :

• MRD 검사 시설
• MRD 검사 병원
• MRD 검사 회사
• MRD 검사 센터
• MRD 검사 건수
• MRD 시장

목차

미국의 MRD 검사 개요

미국의 MRD 검사 시장 규모 및 예측

미국의 MRD 검사 시장의 기술 상황

미국의 MRD 검사 시장의 최종 사용자 통계

미국의 MRD 검사 시장 역학 : 주요 성장 촉진요인

미국의 MRD 검사 시장 역학 : 주요 과제

미국의 MRD 검사 시장 역학 : 시장 기회

미국의 MRD 검사 시설 프로파일

영문목차

Market Analysis of MRD Testing Facility in the U.S.

BIS research is engaged in a study focusing on U.S. MRD ((Minimal Residual Disease) Testing Facilities Market. The report is focused on an overview of MRD testing in U.S., profiles of MRD testing facilities, market size, 2020-2030, technology landscape and key dynamics of the market.

MRD testing plays a crucial role in tracking certain cancers, particularly leukaemia and lymphoma. Many laboratories and medical institutions across the U.S. provide MRD testing services. This type of testing has evolved into an indispensable component of oncology diagnostics and treatment monitoring. Its transformative capabilities, including high sensitivity in detecting residual cancer cells, have propelled the adoption of advanced technologies such as Next-Generation Sequencing (NGS), digital PCR, and flow cytometry.

Objective of the Study

This study aims to systematically profile approximately 200 Minimal Residual Disease (MRD) Testing Facilities across the United States, encompassing the following categories:

• MRD Testing Laboratories
• MRD Testing Hospitals
• MRD Testing Companies
• MRD Testing Centers
• MRD Testing Volume
• MRD Market

The study is focused on profiling about 200 testing facilities in U.S. providing valuable insights for strategic planning, market analysis, and benchmarking. Stakeholders can compare operational metrics, identify underserved regions, and explore partnership opportunities. The detailed test data helps optimize clinical workflows, adopt advanced technologies, and align with industry standards. It also supports compliance with regulatory requirements and enhances funding advocacy. Overall, the report is a comprehensive resource for driving innovation and competitiveness in the MRD testing landscape.

Insights on Geographical Distribution of Facilities in U.S.

Geographical Distribution and Facility Insights

• The distribution of MRD testing facilities across the U.S. highlights regional disparities in access and utilization. States like California, New York, and Texas lead in MRD test volumes, driven by robust healthcare infrastructure and a high incidence of cancer.
• Conversely, states with smaller populations, such as Kansas and Nevada, exhibit lower test volumes but maintain competitive per capita utilization rates. Accredited facilities with CAP and CLIA certifications dominate the landscape, ensuring high-quality testing and compliance with stringent regulatory standards.

The current study also highlights the number of diagnostic laboratories in US testing MRD. California reported the highest number of MRD testing facilities in 2022 with a test volume of 156,658 and test per Capita 401. New York and Texas also followed California in testing facilities. However, Missouri and Utah reported the lowest test volume i.e. 2,554 and 2,720 respectively.

Moreover, companies are also carrying out MRD testing at a higher volume. For instance, Adaptive Biotechnologies carried out 36,871 NGS-based MRD clonoSEQ tests in 2022 as compared to 22,516 NGS-based MRD clonoSEQ tests in 2021. Company reported 51% Y-o-Y growth. Hence, this rising volume of MRD testing is anticipated to boost the overall market growth.

Market Size Estimates, 2020-2030

The U.S. MRD testing market is poised to reach $1,667.5 million by 2030, with a CAGR of 14.18% during the forecast period 2024 and 2030. U.S. testing facilities market accounted for a substantial 39.53% share in 2023 in the overall global MRD testing facilities. In the U.S., several facilities offer MRD testing, with factors such as technology used, test accuracy, and clinical expertise driving the choice of where to get tested.

Report also focuses on the market dynamics, technology landscape and challenges of the market

• The robust growth of the MRD testing market in the U.S. can be attributed to a confluence of factors, including increasing cancer incidence, rising demand for personalized treatment, and rapid advancements in molecular diagnostics. According to the American Cancer Society, leukemia accounted for 13% of adolescent cancer diagnoses in 2022, while myeloma diagnoses exceeded 34,000 cases in the same year. Furthermore, based on the findings of the study. hospitals and specialty clinics dominate the end-user segment, comprising 44.01% of the market in 2023. This sector's strategic integration of MRD testing into oncology services reflects the growing emphasis on personalized medicine. Research institutions and diagnostic laboratories also contribute significantly, with anticipated CAGRs of 14.1% and 13.3%, respectively, during the forecast period. These segments highlight the expanding role of MRD testing in clinical trials and routine diagnostics.

Conclusion

The increasing adoption of these advanced technologies is revolutionizing MRD testing, making it more precise, accessible, and essential for shaping cancer treatment approaches. As the field evolves, there is a growing emphasis on developing personalized treatment plans informed by the in-depth genetic data obtained through MRD testing.

The U.S. MRD testing market is at the forefront of oncology diagnostics, characterized by continuous innovation, strategic collaborations, and a growing emphasis on personalized medicine. While challenges such as cost barriers and sensitivity limitations persist, advancements in companion diagnostics, Medicare coverage expansion, and clinical trials offer promising solutions. By addressing these hurdles and leveraging emerging opportunities, the MRD testing market is well-positioned to enhance cancer care and improve patient outcomes in the years to come.

Table of Contents

Overview of MRD Testing in the U.S.

U.S. MRD Testing Market Size, 2020-2030

U.S. MRD Testing Market Technology Landscape

U.S. MRD Testing Market End-User Stats

U.S. MRD Testing Market Dynamics: Key Drivers

U.S. MRD Testing Market Dynamics: Key Challenges

U.S. MRD Testing Market Dynamics: Market Opportunities

U.S. MRD Testing Facility Profiles